- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Immediately suspend use of Magnex, Magnex Forte, Zosyn, Magnamycin: Pfizer warns doctors, chemists against use of 4 antibiotics
New Delhi: Citing an alert on "deviation in manufacturing process", drug major Pfizer has initiated temporary suspension of the sale and use of its life-saving antibiotic Magnex, Magnex Forte, Zosyn and Magnamycin in India with immediate effect.
The antibiotics, Magnex, Magnex Forte, Magnamycin and Zosyn, are all prescribed to treat various types of bacterial infections and can be used only under medical observation.
In a letter written to stockists, distributors and hospitals issued on May 16, Pfizer said, “You are requested not to undertake any further sale, distribution of the products for all stock-keeping units (SKUs) in your possession, with immediate effect, till further notice from Pfizer.’’
The company said the decision was taken due to some “deviations” at the manufacturing facility of the flagged drugs. The letter further identified the manufacturer as ‘Astral Steritech Private Limited’. The company was informed by its contract manufacturer in India, Astral, that it has observed an out-of-specification during a routine environmental monitoring of its manufacturing block.
“Whilst the manufacturer is currently investigating the matter, they have requested Pfizer, as an abundant precautionary measure and as per best practices, to temporarily suspend the sale/distribution/supply and use of the aforementioned products, pending the investigation by the manufacturers…” the pharma major said in a statement.
However, Pfizer assured that all reasonable efforts are being taken to resolve the matter.
“We will keep you informed on the investigation and further steps to be taken in this regard,” Pfizer added.
Important notice for doctors esp. intensivists (from @pfizer)
— Dr Sudhir Kumar MD DM (@hyderabaddoctor) May 17, 2023
Stop using these life-saving antibiotics for your patients in ICU or wards- Magnex, Magnex forte, Zosyn and Magnamycin- until further information (due to deviations observed in manufacturing process).#MedTwitter pic.twitter.com/Dcazx4yLPo
Meanwhile, the All-India Organization of Chemists and Druggists (AIOCD) swung into action to alert chemists across the country and has written to its state units to suspend the sale, distribution and supply of these products immediately.
"In light of these observations, it is imperative that you immediately inform all trade and hospital stakeholders in your respective states and districts to temporarily suspend the sale, distribution, supply, and do not use of the aforementioned products till further notice," Rajiv Singhal, general secretary, AIOCD, said in a letter.
To elaborate, Magnex is prescribed to treat different types of bacterial infection; Zosyn is used to treat many different infections caused by bacteria, such as stomach infections, skin infections, pneumonia, and severe uterine infections.
Both Magnamycin injections and Magnex Forte are also used to treat bacterial infections such as ear, sinus, throat, lung, urinary tract, skin and soft tissues.
In a regulatory filing, the company said it has decided to initiate a voluntary recall of Magnex (1gm, 2gm), Magnex Forte (1.5gm, 3gm), Zosyn (4.5gm) and Magnamycin (250mg, 1gm, 2gm).
Though the company mentioned that the decision is likely to have an impact on the revenue and profitability of the company, it said that it places the utmost emphasis on patient safety and product quality at every step in the manufacturing and supply chain process.
The said products recorded a sale of Rs 139 crore for the year ended on March 31, 2023, Pfizer told PTI.
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751